Li Liu

发表

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

L. Tsvetkov, J. Smothers, A. Hoos, 2015, Clinical Cancer Research.

Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

P. Bonate, M. Shah, Z. Wainberg, 2013, PloS one.

Local injection of Lenti‐Olig2 at lesion site promotes functional recovery of spinal cord injury in rats

Yuan Liu, Z. Long, Ya-min Wu, 2017, CNS neuroscience & therapeutics.

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

T. Gilmer, J. Greger, S. Laquerre, 2012, Molecular Cancer Therapeutics.

Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib

Sung-Bae Kim, B. Gril, J. Kurebayashi, 2010, Japanese journal of clinical oncology.

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

Joel Greshock, R. Annan, J. Greshock, 2009, Cancer research.

Preclinical Development Combinations of BRAF , MEK , and PI 3 K / mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK 2118436 Dabrafenib , Mediated by NRAS or MEK Mutations

T. Gilmer, J. Greger, S. Laquerre, 2012 .

Preclinical Development Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER 1-or HER 2-Coactivated Tumor Cells

T. Gilmer, J. Greger, Li Liu, 2011 .

Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells

T. Gilmer, J. Greger, Tona M Gilmer, 2011, Molecular Cancer Therapeutics.

Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.

J. Greshock, K. Bachman, B. Ye, 2013, Oncology reports.

Reduced lncRNA Aim enhances the malignant invasion of triple-negative breast cancer cells mainly by activating Wnt/β-catenin/mTOR/PI3K signaling.

J. Li, Li Liu, Hong Shi, 2017, Die Pharmazie.

Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in combination in BRAF-mutant colorectal carcinoma (CRC) models.

K. Bachman, M. Motwani, J. Zou, 2014 .

Single-cell RNA sequencing reveals enhanced antitumor immunity after combined application of PD-1 inhibitor and Shenmai injection in non-small cell lung cancer

Xiaohui Fan, Li Liu, Penghui Yang, 2023, Cell Communication and Signaling.